NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of “Moderate Buy” by Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $36.75.

A number of equities analysts have recently issued reports on NRXP shares. D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, December 16th. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP opened at $2.33 on Friday. The company’s fifty day moving average price is $2.41 and its 200-day moving average price is $2.78. The firm has a market capitalization of $68.97 million, a price-to-earnings ratio of -0.99 and a beta of 1.62. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $6.83 million. As a group, equities research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NRXP. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after acquiring an additional 993,401 shares during the last quarter. Vanguard Group Inc. boosted its position in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the period. AdvisorShares Investments LLC boosted its position in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the period. Geode Capital Management LLC raised its stake in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.